BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danielsson Borssén Å, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, Nyhlin N, Hultcrantz R, Sangfelt P, Weiland O, Lindgren S, Verbaan H, Werner M. Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients. Scand J Gastroenterol 2015;50:217-23. [PMID: 25483724 DOI: 10.3109/00365521.2014.983154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Gleeson D. Long-Term Outcomes of Autoimmune Hepatitis. Clin Liver Dis (Hoboken) 2019;14:24-8. [PMID: 31391933 DOI: 10.1002/cld.797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015;13:2088-2108. [PMID: 26284592 DOI: 10.1016/j.cgh.2015.08.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
3 Sharma R, Verna EC, Simon TG, Söderling J, Hagström H, Green PHR, Ludvigsson JF. Cancer Risk in Patients With Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Am J Epidemiol 2022;191:298-319. [PMID: 33913487 DOI: 10.1093/aje/kwab119] [Reference Citation Analysis]
4 Hrad V, Abebe Y, Ali SH, Velgersdyk J, Al Hallak M, Imam M. Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterol Res Pract 2016;2016:3432640. [PMID: 27413366 DOI: 10.1155/2016/3432640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 2019;49:1421-30. [DOI: 10.1111/apt.15255] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
6 Kim J, Randhawa H, Sands D, Lambe S, Puglia M, Serrano PE, Pinthus JH. Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. BLC 2021;7:261-78. [DOI: 10.3233/blc-211536] [Reference Citation Analysis]
7 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
8 Jensen MD, Jepsen P, Vilstrup H, Grønbæk L. Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study. Am J Gastroenterol 2021. [PMID: 34622808 DOI: 10.14309/ajg.0000000000001525] [Reference Citation Analysis]
9 Chen ZX, Shao JG, Shen Y, Zhang J, Hua Y, Wang LJ, Qin G. Prognostic Implications of Antibodies to Soluble Liver Antigen in Autoimmune Hepatitis: A PRISMA-Compliant Meta-Analysis. Medicine (Baltimore) 2015;94:e953. [PMID: 26061326 DOI: 10.1097/MD.0000000000000953] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
10 Björnsson ES, Ekbom A. Scandinavian epidemiological research in gastroenterology and hepatology. Scand J Gastroenterol 2015;50:636-48. [PMID: 25881666 DOI: 10.3109/00365521.2015.1034168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Cassim S, Bilodeau M, Vincent C, Lapierre P. Novel Immunotherapies for Autoimmune Hepatitis. Front Pediatr 2017;5:8. [PMID: 28184367 DOI: 10.3389/fped.2017.00008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
12 Valean S, Acalovschi M, Dumitrascu DL, Ciobanu L, Nagy G, Chira R. Hepatocellular carcinoma in patients with autoimmune hepatitis - a systematic review of the literature published between 1989-2016. Med Pharm Rep 2019;92:99-105. [PMID: 31086834 DOI: 10.15386/mpr-1228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1286-304. [PMID: 32363674 DOI: 10.1111/apt.15743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017. [PMID: 29644994 DOI: 10.1038/nrdp.2018.17] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
15 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Sharma R, Verna EC, Söderling J, Roelstraete B, Hagström H, Ludvigsson JF. Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31395-1. [PMID: 33065308 DOI: 10.1016/j.cgh.2020.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int 2019;39:610-20. [DOI: 10.1111/liv.14051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
18 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
19 Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 2017;12:e0182391. [PMID: 28771543 DOI: 10.1371/journal.pone.0182391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 9.6] [Reference Citation Analysis]
21 Bolia R, Srivastava A. Editorial: testing for Epstein-Barr virus and treating autoimmune hepatitis-still a long way to go! Aliment Pharmacol Ther 2022;55:364-5. [PMID: 35040164 DOI: 10.1111/apt.16751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev Syst Biol Med. 2020;e1499. [PMID: 32713091 DOI: 10.1002/wsbm.1499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]